Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, Gilkes A, Thomas I, Johnson S, Canham J, Cavenagh J, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett A, Wilhelm-Benartzi C, Dillon R, Russell NH.
Othman J, et al. Among authors: thomas i.
Blood. 2024 May 9;143(19):1931-1936. doi: 10.1182/blood.2023023096.
Blood. 2024.
PMID: 38364112